Can not agree with your statement that mpl hasn't missed a target, the main endpoint for the phase 2b canine trial was to reach 18 out of 46 dogs showing the required improvement, it failed to reach this.
That is a false statemnentt. Nobody ever said this was going to be a cure for the ultra-aggressive B cell lymphoma in dogs but it did, on average, measurably extend their lives and the point was that it was an alternative to chemo.
Can not agree with your statement that mpl hasn't missed a...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.0¢ | 18.5¢ | $2.617M | 12.78M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 231369 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 50000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
19.0¢ |
Change
0.000 ( 4.17 %) |
||||
| Open | High | Low | Volume | ||
| 23.5¢ | 24.0¢ | 18.5¢ | 9241539 | ||
| Last updated 16.02pm 17/05/2024 ? | |||||
| PAA (ASX) Chart |